Claims for Patent: 7,776,895

Summary for Patent: 7,776,895

Title:	Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Abstract:	The invention provides inhalation devices comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol; or a salt or solvate thereof, inhalation devices comprising formulations and combinations of the compound or a salt or solvate thereof, and methods for the treatment or prophylaxis of a clinical condition in a mammal by employing the inhalation devices.
Inventor(s):	Box; Philip Charles (Stevenage, GB), Coe; Diane Mary (Stevenage, GB), Looker; Brian Edgar (Stevenage, GB), Mann; Inderjit Singh (Stevenage, GB), Procopiou; Panayiotis Alexandrou (Stevenage, GB)
Assignee:	Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:	12/211,322
Patent Claims:	1. An inhaler for delivering a pharmaceutically active compound to the lung, said inhaler comprising one or more containers having a dry powder formulation present therein, said dry powder formulation comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl) phenol; or a pharmaceutically acceptable salt thereof. 2. An inhaler according to claim 1, wherein the compound is present as a pharmaceutically acceptable salt which is a .alpha.-phenyl cinnamate salt. 3. An inhaler according to claim 1, wherein the compound is present as a pharmaceutically acceptable salt which is a 1-naphthoate salt. 4. An inhaler according to claim 1, wherein the compound is present as a pharmaceutically acceptable salt which is an (R)-mandelate salt. 5. An inhaler according to claim 1, wherein the compound is present in particles ranging in size from 1 .mu.m to 10 .mu.m. 6. An inhaler according to claim 1, wherein the dry powder formulation comprises lactose. 7. An inhaler for delivering a pharmaceutically active compound to the lung, said inhaler comprising one or more containers having a dry powder formulation present therein, said dry powder formulation comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl) oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol-triphenyl acetate. 8. An inhaler according to claim 7, wherein the compound is present in particles ranging in size from 1 .mu.m to 10 .mu.m. 9. An inhaler according to claim 7, wherein the dry powder formulation comprises lactose.